A Study to Assess Distribution, Binding, and Retention of the Monoclonal Antibody Trontinemab in the Brain of Healthy Participants and Patients with Alzheimer’s Disease

2023-509900-14-00 Protocol BP45211 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 10 Dec 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol BP45211

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 20
Countries 1
Sites 1

Alzheimer’s Disease (AD)

Key facts

Sponsor
F. Hoffmann-La Roche AG
Participant type
Patients, Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
10 Dec 2024 → ongoing
Decision date (initial)
2024-10-15
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Alzheimer’s Disease (AD)

VersionLevelCodeTermSystem organ class
20.0 LLT 10001896 Alzheimer's disease 10029205

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

F. Hoffmann-La Roche AG

Sponsor organisation
F. Hoffmann-La Roche AG
Address
Grenzacherstrasse 124
City
Basel
Postcode
4058
Country
Switzerland

Scientific contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Public contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 20 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Stichting Amsterdam UMC
Department of Radiology and Nuclear Medicine, De Boelelaan 1117, 1081 HV, Amsterdam

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-12-10 2025-03-05

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-07 Netherlands Acceptable
2024-10-15
2024-10-15
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-02-13 Netherlands Acceptable
2024-10-15
2025-02-13
3 NON SUBSTANTIAL MODIFICATION NSM-2 2025-03-21 Netherlands Acceptable
2024-10-15
2025-03-21
4 SUBSTANTIAL MODIFICATION SM-2 2025-07-18 Netherlands Acceptable
2025-08-15
2025-08-15
5 NON SUBSTANTIAL MODIFICATION NSM-3 2026-04-29 Netherlands Acceptable
2025-08-15
2026-04-29